Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
McKesson
Harvard Business School
Baxter
Dow

Last Updated: December 16, 2019

DrugPatentWatch Database Preview

Heparin sodium - Generic Drug Details

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What are the generic drug sources for heparin sodium and what is the scope of freedom to operate?

Heparin sodium is the generic ingredient in thirty-eight branded drugs marketed by Hospira, Intl Medication, Luitpold, Parke Davis, Smith And Nephew, Solopak, Abraxis Pharm, Akorn, B Braun Medical Inc, Casi Pharms Inc, Chamberlin Parenterl, Dell Labs, Dr Reddys, Fresenius Kabi Usa, Gland Pharma Ltd, Hikma, Hospira Inc, Lilly, Mylan Labs Ltd, Nanjing King-friend, Organon Usa Inc, Pfizer, Pharm Spec, Pharmacia And Upjohn, Sagent Pharms, Sandoz, Shenzhen Techdow, Watson Labs Inc, West-ward Pharms Int, Baxter Hlthcare, Mcgaw, B Braun, Pharma Serve Ny, and 3M, and is included in eighty NDAs. Additional information is available in the individual branded drug profile pages.

There are seventy-seven drug master file entries for heparin sodium. Eighteen suppliers are listed for this compound.

Drug Prices for heparin sodium

See drug prices for heparin sodium

Recent Clinical Trials for heparin sodium

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Universidad Nacional Autonoma de MexicoPhase 4
Hospital General “Dr. Miguel Silva” de MoreliaPhase 4
NAUSLIFE HEMODIALYSIS CLINICSPhase 4

See all heparin sodium clinical trials

Pharmacology for heparin sodium

US Patents and Regulatory Information for heparin sodium

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abraxis Pharm SODIUM HEPARIN heparin sodium INJECTABLE;INJECTION 017033-004 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Baxter Hlthcare HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER heparin sodium INJECTABLE;INJECTION 018609-001 Apr 28, 1982 AP RX No No   Start Trial   Start Trial   Start Trial
Hospira HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER heparin sodium INJECTABLE;INJECTION 019339-002 Mar 27, 1985 AP RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Colorcon
Boehringer Ingelheim
AstraZeneca
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.